Reuters logo
BRIEF-Shire says CHMP recommends EU marketing authorization for ADYNOVI [Antihemophilic Factor (Recombinant), PEGylated]
November 13, 2017 / 6:13 AM / 9 days ago

BRIEF-Shire says CHMP recommends EU marketing authorization for ADYNOVI [Antihemophilic Factor (Recombinant), PEGylated]

Nov 13 (Reuters) - SHIRE PLC:

* CHMP RECOMMENDS EU MARKETING AUTHORIZATION FOR ADYNOVI [antihemophilic factor (recombinant), pegylated] FOR ADULTS AND ADOLESCENTS WITH HEMOPHILIA A​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below